CD19 and infection: With particular relevance to CD19-CAR T-cell therapy, patients treated with CD19-CAR T cells may experience prolonged B-cell aplasia and hypogammaglobulinemia [33, 34], conditions that often require intermittent antibiotics administration and immunoglobulin replacement to reduce the risk of infection [35, 36].